Approval is based on results from SOLAR-1, where PIQRAY®in combination with fulvestrant nearly doubl
READ MORE 2020-08-20News List
PIQRAY® is approved and now available in Canada as the first and only treatment specifically for patients with a PIK3CA mutation in HR-positive, HER2-negative advanced breast cancer
Gastrointestinal stromal tumor (GIST) targeted new drugs! Avapritinib will be approved in the EU in September
Blueprint Medicines announced that the European Medicines Agency (EMA) Committee for Medicinal Produ
READ MORE 2020-07-29
Gilead's Veklury has been approved：Veklury is the First Approved Treatment Option for COVID-19 in the European Union
At present,The COVID-19 epidemic continues to spread rapidly around the world. As of 01am, July 04,
READ MORE 2020-07-05
Announcement on the extension of CPHI North America 2020 in September
Dear Customers,Unfortunately, we have to cancel the plan for our participation in the CPHI North Ame
READ MORE 2020-06-18
New medicine for insomnia! Eisai double-acting orexin receptor antagonist Dayvigo (lemborexant) is launched in the US!
Japanese pharmaceutical company Eisai recently announced the launch of Dayvigo (lemborexant), a new
READ MORE 2020-06-16
The first c-Met inhibitor approved by the FDA to market
On May 6, the FDA approved the listing of Novartis Tabrecta (capmatinib) for the treatment of patien
READ MORE 2020-05-18
The cortisol synthesis inhibitor Isturia developed by Recordati has been approved by the European Union!
On January 16, 2020, the Italian pharmaceutical company Recordati recently announced that the Europe
READ MORE 2020-04-09
Fapilavir completes clinical research and shows good clinical efficacy
On March 17th, the State Council's joint prevention and control mechanism held a press conferenc
READ MORE 2020-03-22
Migraine relieved within 1 hour, FDA approves new oral medication
2020.02.27, Biohaven announced that the US FDA has approved the company's CGRP receptor inhibito
READ MORE 2020-03-01
Insomnia and schizophrenia innovative treatments approved
Dayvigo (lembroexant) developed by Eisai is an orexin receptor antagonist. Orexin is a neuropeptide
READ MORE 2020-02-03